Background: Polycystic ovary syndrome (PCOS) is a common hormonal imbalance among women in reproductive age and is the main cause of their infertility due to anovulatory. PCOS is not a specific endocrine disorder with a single cause, but is a syndrome with different signs and symptoms. Anti-mullerian hormone (AMH) is a regulator hormone in folliculogenesis and its serum level increases about two or three folds in PCOS patients relative to healthy women. Sitagliptin, as an oral antihyperglycemic agent uses in treatment of diabetes mellitus type 2, is considered recently in clinical investigations of PCOS. Objective: The aim of this study was to evaluate the effect of sitagliptin on the level of AMH in PCOS patients suffering from infertility. Materials and Methods: In this clinical trial, 40 infertile PCOS patients were selected based on the Rotterdam criteria; Then they divided into 2 groups (n=20): sitagliptin group (treated with 50 mg of sitagliptin/ two times per day) and placebo group . All patients were undergoing treatment with antagonist GnRH protocol. In all groups, medications were administrated from the day 3 of the previous cycle until ovum pick-up. Serum levels of AMH was measured in the groups before and after treatment. Data was analyzed statistically using paired samples t-test at p<0.05. Result: Serum AMH level was significantly decreased after treatment with sitagliptin (5.41±1.09 vs.7.17±1.56). Conclusion: Our obtained result from this clinical study showed that sitagliptin can decrease the serum level of AMH in women with infertility due to PCOS. Therefor it seems that sitagliptin has therapeutic efficiency for treatment of PCOS.
